The Allevi Liver dECM promises the fabrication of liver tissue that has a more representative physiological function. The product uses a combination of a type I collagen Allevi bioink for patterning as well as Xylyx Bio’s highly desired liver-specific TissueSpec® ECM to enhance specialized biological response.
Xylyx Bio products for cell culture are obtained from porcine or human tissue sources and processed to various formats, enabling cell culture models that are significantly more predictive of physiology. Their 3D TissueSpec® ECM hydrogels and scaffolds provide support to cell culture models, facilitating the acceleration of drug discovery, development and tissue regeneration.
“We are thrilled to partner with Allevi and share our expertise in tissue-specific ECM,” stated Andrea Nye, Chief Executive Officer at Xylyx Bio. “Recognizing the importance of the native cellular microenvironment, Xylyx Bio harnesses the body’s innate biology in the form of tissue-specific extracellular matrix. By sourcing extracellular matrix from native organs and tissues, Xylyx produces tissue-specific substrates that comprise both the mechanical properties and complex ratios of ECM components specific and unique to each tissue and organ type.”
Founded in 2014, Allevi claims that its “mission is to provide users the ability to design, engineer, and manufacture 3D tissue.” To deliver important building blocks and provide users with the best experience possible to drive new scientific discoveries, Allevi is hopeful that the new dECM bioink will provide scientists a revolutionary approach that allows scientists to print 3D tissue structures with biochemical and mechanical features inherent in human physiology.
[Images: Allevi and Xylyx Bio]
Xylyx Bio’s Co-founder and Chief Strategy Officer, John O’Neil, added that a “deeper understanding of the comprehensive nature of tissues and cells and their interaction with the cellular microenvironment – that is, the extracellular matrix – holds great promise to lead to a paradigm shift in 3D bioprinting, allowing researchers to study physiologic activity of cells in vitro towards a better understanding of disease and development of more effective drugs and treatments.”
You May Also Like
3 Key Indicators of Great Company Culture
Additive manufacturing is not immune to the thread that binds a team or company together. A thread better known as ‘company culture.’ Each business has one, each one is different....
Hyperganic Raises $7.8M in First Venture Round for AI-Driven 3D Printing
Embarking on a journey to recreate nature’s most complex designs through artificial intelligence (AI) and 3D printing, German company Hyperganic raised $7.8 million in its first venture round on February...
3D Printing Financials: Voxeljet Revenue up 80% since Last Earnings Report, Losses Deepen Year-over-Year
Industrial 3D printer manufacturer voxeljet (Nasdaq: VJET) reported fourth-quarter net losses for 2020 of €3.7 million ($4.3 million) after posting similar losses in the same period a year earlier. The...
3D Printing Financials: SLM Solutions Reports Losses of €30M for 2020, Revenues Up 26%
SLM Solutions (AM3D.DE) reported a €30 million ($35 million) loss for the year ending December 31, 2020, with revenues at €62 million ($73 million) versus €49 million ($58 million) in...
View our broad assortment of in house and third party products.